CCK antagonists: pharmacology and therapeutic interest.
CCK was first identified and characterized in the digestive tract where it is known to be a factor involved in the control of gut motility. Later, CCK and CCK receptors were identified in regions of the central nervous system that are associated with the control of emotion, motivation and sensory processing. The recent discovery and development of CCK-receptor antagonists having selective affinity for either CCKA or CCKB receptors has led to a better understanding of the functional role of CCK and its binding sites in the brain and periphery. Some of these compounds are being examined in man for their therapeutic usefulness in mental as well as in digestive disorders. This review will highlight the results from both basic and clinical investigations that have examined the effects of selective CCK receptor ligands. The focus will be on the central nervous system pharmacology of CCK antagonists and the involvement of CCK in gastrointestinal and colonic motility.
Institut de Recherche Jouveinal, Fresnes, France.
J G
JG
Wettstein
L
L
Buéno
J L
JL
Junien
D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy / Q000209:etiology; D001921:Brain / Q000187:drug effects / Q000502:physiology; D002490:Central Nervous System / Q000187:drug effects; D002766:Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000502:physiology; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008568:Memory / Q000187:drug effects; D010146:Pain / Q000517:prevention & control; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors
D011949:Receptors, Cholecystokinin; D002766:Cholecystokinin